Literature DB >> 3041855

Monoclonal and polyclonal antibodies both block and enhance transmission of human Plasmodium vivax malaria.

J S Peiris1, S Premawansa, M B Ranawaka, P V Udagama, Y D Munasinghe, M V Nanayakkara, C P Gamage, R Carter, P H David, K N Mendis.   

Abstract

Antibodies against gametes of the malarial parasite inhibit the development of the parasite in the mosquito and curtail the transmission of malaria. We now report that a monoclonal antibody against gametes of the human malaria pathogen Plasmodium vivax and antibodies induced during natural infections of P. vivax in humans which suppress infectivity of the parasites to the vector at high concentrations can, at lower concentrations, have the opposite effect and enhance the level of malaria infection in the mosquitoes. Infectivity enhancing effects of up to 12-fold were demonstrated when a transmission blocking monoclonal antibody and immune human sera were diluted, in some undiluted immune human sera, and in the sera of vivax malaria patients during convalescence after drug cure.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3041855     DOI: 10.4269/ajtmh.1988.39.26

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  24 in total

1.  A mathematical model for Plasmodium vivax malaria transmission: estimation of the impact of transmission-blocking immunity in an endemic area.

Authors:  A P De Zoysa; C Mendis; A C Gamage-Mendis; S Weerasinghe; P R Herath; K N Mendis
Journal:  Bull World Health Organ       Date:  1991       Impact factor: 9.408

2.  Analysis of immunity induced by the affinity-purified 21-kilodalton zygote-ookinete surface antigen of Plasmodium berghei.

Authors:  N Tirawanchai; L A Winger; J Nicholas; R E Sinden
Journal:  Infect Immun       Date:  1991-01       Impact factor: 3.441

Review 3.  Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America.

Authors:  Myriam Arévalo-Herrera; Yezid Solarte; Catherin Marin; Mariana Santos; Jenniffer Castellanos; John C Beier; Sócrates Herrera Valencia
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

Review 4.  Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination.

Authors:  Teun Bousema; Chris Drakeley
Journal:  Clin Microbiol Rev       Date:  2011-04       Impact factor: 26.132

Review 5.  Future potential of malaria vaccines.

Authors:  M Hommel
Journal:  J R Soc Med       Date:  1989       Impact factor: 5.344

Review 6.  Status of malaria vaccine research.

Authors:  G A Targett
Journal:  J R Soc Med       Date:  1989       Impact factor: 5.344

7.  Optimized in vitro production of Plasmodium vivax ookinetes.

Authors:  Colleen M McClean; Haydee Guerra Alvarado; Victor Neyra; Alejandro Llanos-Cuentas; Joseph M Vinetz
Journal:  Am J Trop Med Hyg       Date:  2010-12       Impact factor: 2.345

Review 8.  Current status of malaria and potential for control.

Authors:  R S Phillips
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

9.  Baculovirus-vectored multistage Plasmodium vivax vaccine induces both protective and transmission-blocking immunities against transgenic rodent malaria parasites.

Authors:  Masanori Mizutani; Mitsuhiro Iyori; Andrew M Blagborough; Shinya Fukumoto; Tomohiro Funatsu; Robert E Sinden; Shigeto Yoshida
Journal:  Infect Immun       Date:  2014-08-04       Impact factor: 3.441

10.  Population biology of malaria within the mosquito: density-dependent processes and potential implications for transmission-blocking interventions.

Authors:  Thomas S Churcher; Emma J Dawes; Robert E Sinden; George K Christophides; Jacob C Koella; María-Gloria Basáñez
Journal:  Malar J       Date:  2010-11-04       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.